HP8 FINANCIAL IMPACT OF A PRIOR-AUTHORIZATION RESTRICTION FOR PIMECROLIMUS 1% CREAM IN THE TREATMENT OF ATOPIC DERMATITIS

Pimecrolimus 1% cream (Elidel) for atopic dermatitis.

Pimecrolimus is an immunomodulating medication that inhibits production of inflammatory cytokines in the skin and this compound was specifically developed for the treatment of inflammatory skin diseases. Phase II and III clinical trials with the topical formulation of pimecrolimus (Elidel cream, Novartis) have shown that it is safe and effective for use in patients with atopic dermatitis (AD). ...

Is pimecrolimus cream (1%) an appropriate therapeutic agent for the treatment of external ear atopic dermatitis?

BACKGROUND In recent years, pimecrolimus 1% cream has been demonstrated to reduce symptoms of atopic dermatitis in patients when applied topically. MATERIAL/METHODS In our study we compared the therapeutic effects of local 1% pimecrolimus to 1% hydrocortisone, and to a control group in a mouse model with atopic dermatitis in the external ear canals. Atopic dermatitis was created by applicatio...

Pimecrolimus for the treatment of atopic dermatitis

Pimecrolimus Cream 1% in the Management of Atopic Dermatitis in Pediatric Patients: A Meta-Analysis

OBJECTIVE To evaluate the efficacy and safety of pimecrolimus cream 1% in the treatment of AD in the pediatric population. METHODS PubMed, EMBASE, Web of Science and Cochrane library databases were searched till July 2013. The randomized and nonrandomized blinded studies of pimecrolimus cream 1% applied twice daily with Jaded score ≥ 3 in pediatric patients with AD were included. The efficacy...

Retraction: Pimecrolimus Cream 1% in the Management of Atopic Dermatitis in Pediatric Patients: A Meta-Analysis

After the publication of the article, a group of readers raised concerns about several aspects of the methodology for the metaanalysis and the interpretation of the results (http://www.plosone. org/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone. 0093095). Upon follow-up with the authors and consultation with editorial board members, the following concerns have been identified: * The inter...